A team of scientists from the US National Institutes of Health and the pharmaceutical company Sanofi developed an antibody able to attack 99% of HIV strains and can prevent infection in primates. Human trials believed to start in 2018 in order to see if it can prevent or treat an infection.
This development combined three antibodies into a more powerful try-specific antibody.
Dr Gary Nabel, the chief scientific officer at Sanofi and one of the report authors, explains: “They are more potent and have greater breadth than any single naturally occurring antibody that’s been discovered. We’re getting 99% coverage, and getting coverage at very low concentrations of the antibody.”